ChondroGene to Present at BioFinance 2006
TORONTO, CANADA (May 1, 2006): ChondroGene™ Limited (TSX Venture: CDG) reported today that Dr. K. Wayne Marshall, President & CEO, will be presenting at the upcoming BioFinance 2006 meeting being held in Toronto from May 2 to 4 at the Toronto Marriott Eaton Centre. ChondroGene’s presentation will take place on Wednesday May 3rd at 9:00 AM in the Trinity II room.
About BioFinance 2006
BioFinance 2006 is the Canadian Life Science industry's leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia. For further information, visit http://www.biofinance.ca/BioFinance.About GeneNews
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle™, to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle™ in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product, ColonSentry™, is a convenient and patient-friendly blood-based test that can assess an individual's current risk for colorectal cancer. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.